(Q37841547)

24 August 2017

1 reference

title

Current options and new developments in the treatment of haemophilia (English)

1 reference

24 August 2017

0 references

Trisha Wong

1

1 reference

24 August 2017

Michael Recht

series ordinal

2

1 reference

24 August 2017

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

305-320

1 reference

The tragic history of AIDS in the hemophilia population, 1982-1984.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Hepatitis C antibody and chronic liver disease in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Generalized lymphadenopathy and T cell abnormalities in hemophilia A

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

HIV infection in haemophilia--a European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Characterization of the human factor VIII gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Molecular cloning of a cDNA encoding human antihaemophilic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Coagulation factor concentrates: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Clinical perspectives of emerging pathogens in bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Haemophilia prophylaxis in young patients--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Prophylaxis for severe haemophilia: clinical and economical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Thrombogenic materials in prothrombin complex concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Molecular cloning of the gene for human anti-haemophilic factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Advances in hemophilia: experimental aspects and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Inhibitor antibodies to factor VIII and factor IX: management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Inhibitors occur more frequently in African-American and Latino haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Inhibitors of factor VIII in black patients with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Factor Xa and prothrombin: mechanism of action of FEIBA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Views on methods for monitoring recombinant factor VIIa in inhibitor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Catalytic activity of antibodies against factor VIII in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Serial plasmapheresis in a haemophiliac with antibodies to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Successful cardiac surgery following plasmapheresis in a patient with hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Hemophilia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

DDAVP factor VIII concentrate and its properties in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Treatment of hemophilia A and von Willebrand's disease patients with an intranasal dripping of DDAVP

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Peptide and protein PEGylation: a review of problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Extending half-life in coagulation factors: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

The tertiary structure and domain organization of coagulation factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Pharmaceutical strategies utilizing recombinant human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Clinical gene transfer studies for hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Gene therapy for hemophilia: clinical trials and technical tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

PHENOTYPIC REPAIR BY STREPTOMYCIN OF DEFECTIVE GENOTYPES IN E. COLI

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585340-000000000-00000

Myocardial necrosis after therapy with prothrombin-complex concentrate

21 January 2018

1 reference

12 December 2020

The role of immunomodulation in the management of factor VIII inhibitors

1 reference

12 December 2020

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

1 reference

12 December 2020

Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B

1 reference

12 December 2020

Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.

1 reference

12 December 2020

Hepatitis and Clotting-Factor Concentrates

1 reference

12 December 2020

Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII

1 reference

12 December 2020

Gene therapy for haemophilia

1 reference

12 December 2020

Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients

1 reference

12 December 2020

Clinical use of a new glycine-precipitated antihemophilic fraction

1 reference

12 December 2020

Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations

1 reference

12 December 2020

Plasmapheresis: its value in the management of patients with antibodies to factor VIII.

1 reference

12 December 2020

Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin

1 reference

12 December 2020

Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A

1 reference

12 December 2020

The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.

1 reference

12 December 2020

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors

1 reference

12 December 2020

Prophylaxis with Factor Concentrates in Preventing Hemophilic Arthropathy

1 reference

12 December 2020

Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery

1 reference

12 December 2020

A possible mechanism of action of activated factor VII independent of tissue factor

1 reference

12 December 2020

Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor

1 reference

12 December 2020

Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion

1 reference

12 December 2020

The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors

1 reference

12 December 2020

A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors

1 reference

12 December 2020

The gene structure of human anti-haemophilic factor IX.

1 reference

12 December 2020

Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity

1 reference

12 December 2020

10.2165/11585340-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1017148388

0 references

1 reference